Eurobio Scientific S.A.
ALERS.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | €259 | €183 | €208 | €292 |
| - Cash | €22 | €49 | €47 | €93 |
| + Debt | €34 | €101 | €114 | €16 |
| Enterprise Value | €271 | €235 | €274 | €215 |
| Revenue | €155 | €131 | €153 | €185 |
| % Growth | 18.6% | -14.4% | -17.4% | – |
| Gross Profit | €72 | €57 | €65 | €97 |
| % Margin | 46.4% | 44% | 42.6% | 52.8% |
| EBITDA | €20 | €25 | €40 | €80 |
| % Margin | 13.2% | 18.8% | 26.5% | 43.1% |
| Net Income | €4 | €5 | €25 | €61 |
| % Margin | 2.6% | 3.7% | 16.3% | 32.8% |
| EPS Diluted | 0.39 | 0.43 | 2.2 | 5.57 |
| % Growth | -9.3% | -80.5% | -60.5% | – |
| Operating Cash Flow | €17 | €27 | €42 | €65 |
| Capital Expenditures | -€3 | -€4 | -€3 | -€2 |
| Free Cash Flow | €13 | €23 | €39 | €64 |